First Trust Advisors LP Lowers Stock Holdings in Insmed, Inc. $INSM

First Trust Advisors LP cut its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 7.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 229,563 shares of the biopharmaceutical company’s stock after selling 18,377 shares during the quarter. First Trust Advisors LP’s holdings in Insmed were worth $37,538,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. iA Global Asset Management Inc. grew its position in shares of Insmed by 15,973.5% during the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock worth $4,644,000 after buying an additional 26,516 shares in the last quarter. Monashee Investment Management LLC bought a new stake in shares of Insmed in the fourth quarter valued at about $8,702,000. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Insmed by 89.5% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 103,308 shares of the biopharmaceutical company’s stock worth $17,981,000 after acquiring an additional 48,779 shares during the period. Aberdeen Group plc lifted its stake in Insmed by 7.9% in the fourth quarter. Aberdeen Group plc now owns 253,112 shares of the biopharmaceutical company’s stock worth $44,052,000 after acquiring an additional 18,490 shares during the period. Finally, Danske Bank A S grew its holdings in Insmed by 4,494.1% during the 4th quarter. Danske Bank A S now owns 110,258 shares of the biopharmaceutical company’s stock worth $19,189,000 after acquiring an additional 107,858 shares in the last quarter.

Insmed Stock Performance

Shares of INSM opened at $104.73 on Tuesday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The firm has a market cap of $22.70 billion, a PE ratio of -18.21 and a beta of 0.78. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75. The stock has a fifty day moving average price of $105.15 and a 200-day moving average price of $132.75.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same period in the previous year, the business earned ($1.42) EPS. The firm’s revenue for the quarter was up 229.7% on a year-over-year basis. Equities research analysts predict that Insmed, Inc. will post -2.43 earnings per share for the current fiscal year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 10,699 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $117.40, for a total value of $1,256,062.60. Following the transaction, the chief executive officer owned 259,058 shares in the company, valued at approximately $30,413,409.20. This represents a 3.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 1,806 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total transaction of $173,050.92. Following the completion of the sale, the insider owned 37,648 shares in the company, valued at $3,607,431.36. The trade was a 4.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 54,590 shares of company stock valued at $5,793,738 over the last three months. 2.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Barclays boosted their price target on shares of Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Friday, July 17th. Royal Bank Of Canada dropped their target price on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Wednesday, June 10th. Finally, Mizuho set a $192.00 price objective on Insmed in a research note on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $209.13.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.